2015•Rheumatology InternationalRequires access

Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry

M. Cárdenas, Soraya de la Fuente, Pilar Font, Carmen Castro, Manuel Romero‐Gómez, D. Ruiz, J. Calvo-Gutiérez, Alejandro Escudero‐Contreras, M.Á. Casado, José Ramón Del Prado, Eduardo Collantes‐Estévez

Open publisher page 12 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Etanercept, Adalimumab, Medicine, Infliximab, Rheumatoid arthritis, Internal medicine, Surgery, Tumor necrosis factor alpha